4,5-Dihydro-4,4-dimethyl-2-[[3-(2-nitrophenyl)methyl]-2-thienyl]-oxazole | 167770-27-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,5-Dihydro-4,4-dimethyl-2-[[3-(2-nitrophenyl)methyl]-2-thienyl]-oxazole
• 英文别名: 4,5-dihydro-4,4-dimethyl-2-[3-[(2-nitrophenyl)methyl]-thien-2-yl]oxazole；4,5-dihydro-4,4-dimethyl-2-[3-[(2-nitrophenyl)methyl]-2-thienyl]oxazole；4,4-dimethyl-2-[3-[(2-nitrophenyl)methyl]thiophen-2-yl]-5H-1,3-oxazole
• CAS: 167770-27-6
• 化学式: C₁₆H₁₆N₂O₃S
• 分子量: 316.381
• InChiKey: XAVIWRMECNCTEF-UHFFFAOYSA-N

物化性质

• 沸点：
  461.2±40.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  95.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,5-Dihydro-4,4-dimethyl-2-[[3-(2-nitrophenyl)methyl]-2-thienyl]-oxazole 在 盐酸 、 锌 作用下， 以 acetone - water 、 溶剂黄146 为溶剂， 生成 9,10-Dihydro-4H-thieno[2,3-c][1]benzazepin-10-one
  参考文献：
  名称：

  Process for the preparation of tricyclic-heterocycles

  摘要：

  该公式的化合物：##STR1## 其中R.sup.1为H，C.sub.1-C.sub.3烷基，C.sub.1-C.sub.3烷氧基，氨基，溴基，氯基，氟基，碘基，C.sub.1-C.sub.3烷基羰基或三氟甲基；R.sup.2为H，C.sub.1-C.sub.3烷基，C.sub.1-C.sub.3烷氧基，溴基，氯基，氟基，碘基或C.sub.1-C.sub.3烷基羰基；或R.sup.1和R.sup.2一起为亚甲二氧基或乙二氧基；结构##STR2## 表示如说明书所述，一个ortho-融合苯基；一个含N，O或S的芳香5元杂环；或一个含N的芳香6元杂环；所有这些都可能被选择地取代，通过##STR3##的反应产生，其中R.sup.3是一个掩蔽的醛或羧基，随后是2-硝基苄溴的去除，还原和环化。

  公开号：

  US05436333A1
• 作为产物：
  描述：

  4,4-dimethyl-2-(2-thienyl)oxazoline 、 2-硝基苄溴 在 四(三苯基膦)钯 、 正丁基锂 、 三丁基氯化锡 作用下， 生成 4,5-Dihydro-4,4-dimethyl-2-[[3-(2-nitrophenyl)methyl]-2-thienyl]-oxazole
  参考文献：
  名称：

  4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists

  摘要：

  Synthesis and structure-activity relationships (SAR) of arginine vasopressin receptor (AVP) antagonists are described. Potent and orally active compounds are prepared when tricyclic 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine moiety in VPA-985 1 is replaced with a compound 7 or 12. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00278-4

文献信息

• Process for the preparation of tricyclic-heterocycles
  申请人：American Cyanamid Company

  公开号：US05436333A1

  公开（公告）日：1995-07-25

  Compounds of the formula: ##STR1## in which R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, amino, bromo, chloro, fluoro, iodo, C.sub.1 -C.sub.3 alkylcarbonyl or trifluoromethyl; R.sup.2 is H, C.sub.1 -C.sub.3 alkyl, C.sub.1 --C.sub.3 alkoxy, bromo, chloro, fluoro, iodo, or C.sub.1 -C.sub.3 alkylcarbonyl; or R.sup.1 and R.sup.2 taken together are methylenedioxy or ethylenedioxy; the structure ##STR2## represents, as described in the specification, an ortho-fused phenyl moiety; an aromatic 5-membered heterocycle containing N, O, or S; or an aromatic 6-membered heterocycle containing N; all of which may be optionally substituted, are produced by reaction of ##STR3## where R.sup.3 is a masked aldehyde or carboxyl group, with 2-nitro-benzyl bromide followed by removal of the mask, reduction and cyclization.

  该公式的化合物：##STR1## 其中R.sup.1为H，C.sub.1-C.sub.3烷基，C.sub.1-C.sub.3烷氧基，氨基，溴基，氯基，氟基，碘基，C.sub.1-C.sub.3烷基羰基或三氟甲基；R.sup.2为H，C.sub.1-C.sub.3烷基，C.sub.1-C.sub.3烷氧基，溴基，氯基，氟基，碘基或C.sub.1-C.sub.3烷基羰基；或R.sup.1和R.sup.2一起为亚甲二氧基或乙二氧基；结构##STR2## 表示如说明书所述，一个ortho-融合苯基；一个含N，O或S的芳香5元杂环；或一个含N的芳香6元杂环；所有这些都可能被选择地取代，通过##STR3##的反应产生，其中R.sup.3是一个掩蔽的醛或羧基，随后是2-硝基苄溴的去除，还原和环化。
• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05693635A1

  公开（公告）日：1997-12-02

  Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.

  一般式I的三环化合物：##STR1##在此定义下表现出V.sub.1和/或V.sub.2受体的拮抗活性，并在体内表现出抗利尿激素拮抗活性，使用这种化合物治疗由于肾脏过度重吸收水而导致的疾病的方法，以及制备这种化合物的方法。
• Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05686445A1

  公开（公告）日：1997-11-11

  Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.

  一般式I的三环化合物：##STR1##在此定义下，表现出对V.sub.1和/或V.sub.2受体的拮抗活性，并在体内表现出抗利尿激素拮抗活性。本发明提供使用此类化合物治疗由肾水过度重吸收所特征的疾病的方法，并提供制备此类化合物的方法。
• Tricyclic Benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05736538A1

  公开（公告）日：1998-04-07

  Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.

  本发明涉及一般式I的三环化合物：##STR1##在此定义中表现出V.sub.1和/或V.sub.2受体的拮抗活性，并在体内表现出抗利尿激素拮抗活性，使用这种化合物治疗由水的过度肾重吸收所特征的疾病的方法，以及制备这种化合物的过程。
• N-acylated tricyclic azaheterorings useful as vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：EP0640592B1

  公开（公告）日：1998-12-30